FDA Grants Accelerated Approval to Zenbexus (iberdomide) in Combination with Daratumumab and Hyaluronidase-fihj and Dexamethasone for the Treatment of Multiple Myeloma
RegulatoryapprovedZENBEXUSdaratumumab and hyaluronidase-fihjdexamethasonePositive
AI Analysis
Summary
Bristol Myers Squibb announced FDA accelerated approval of ZENBEXUS (iberdomide) in combination with daratumumab and hyaluronidase-fihj and dexamethasone for multiple myeloma treatment. This regulatory approval represents a significant milestone for the company's oncology portfolio.
Outcome Details
FDA Grants Accelerated Approval to ZENBEXUS (iberdomide) in combination with daratumumab and hyaluronidase-fihj and dexamethasone for Multiple Myeloma
Importance:8/10
Sentiment:
0.95
FDA ApprovalAccelerated ApprovalMultiple MyelomaOncologyBristol Myers Squibb
Related Companies
Read the original article
Published by Drugs.com New Drug Approvals on August 13, 2026 10:08 PM